We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+8.48%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$14.8B
AUM Growth
+$629M
Cap. Flow
-$312M
Cap. Flow %
-2.1%
Top 10 Hldgs %
24.14%
Holding
917
New
50
Increased
256
Reduced
457
Closed
57

Top Buys

Rank Stock Value
1
VERU icon
Veru
VERU
+$53M
2
MELI icon
Mercado Libre
MELI
+$43.2M
3
DAR icon
Darling Ingredients
DAR
+$41.7M
4
JNJ icon
Johnson & Johnson
JNJ
+$33.7M
5
MET icon
MetLife
MET
+$31.1M

Top Sells

Rank Stock Value
1
PEP icon
PepsiCo
PEP
+$46.1M
2
NKE icon
Nike
NKE
+$36.6M
3
ITW icon
Illinois Tool Works
ITW
+$35.8M
4
AAPL icon
Apple
AAPL
+$31.9M
5
GILD icon
Gilead Sciences
GILD
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 33.32%
2 Technology 22.84%
3 Financials 10.04%
4 Consumer Discretionary 7.69%
5 Industrials 7.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PBR icon
776
Petrobras
PBR
$116B
$489K ﹤0.01%
45,900
-7,181
-14% -$86.7K
EXPE icon
777
Expedia Group
EXPE
$35.5B
$481K ﹤0.01%
5,487
-1,412
-20% -$134K
TW icon
778
Tradeweb Markets
TW
$22.2B
$471K ﹤0.01%
7,249
-1,602
-18% -$94.2K
ARW icon
779
Arrow Electronics
ARW
$10.8B
$455K ﹤0.01%
4,356
-6,655
-60% -$687K
WYNN icon
780
Wynn Resorts
WYNN
$10.3B
$454K ﹤0.01%
5,511
-3,537
-39% -$259K
LOOP icon
781
Loop Industries
LOOP
$35.6M
$454K ﹤0.01%
190,000
MPT
782
Medical Properties Trust
MPT
$2.89B
$450K ﹤0.01%
40,398
-8,982
-18% -$104K
JBTM
783
JBT Marel
JBTM
$7.59B
$443K ﹤0.01%
+4,853
New +$444K
FNV icon
784
Franco-Nevada
FNV
$40.6B
$442K ﹤0.01%
3,243
STKL
785
DELISTED
SunOpta
STKL
$440K ﹤0.01%
+52,189
New +$493K
DBX icon
786
Dropbox
DBX
$7.48B
$418K ﹤0.01%
18,670
-5,508
-23% -$121K
CCO icon
787
Clear Channel Outdoor Holdings
CCO
$1.23B
$384K ﹤0.01%
365,542
-53,409
-13% -$67.2K
CABO icon
788
Cable One
CABO
$249M
$377K ﹤0.01%
529
-614
-54% -$458K
GTN icon
789
Gray Television
GTN
$430M
$366K ﹤0.01%
32,735
-2,085
-6% -$25.9K
ADV icon
790
Advantage Solutions
ADV
$542M
$362K ﹤0.01%
6,969
-657
-9% -$41.3K
CARS icon
791
Cars.com
CARS
$705M
$359K ﹤0.01%
+26,037
New +$353K
YELP icon
792
Yelp
YELP
$1.51B
$357K ﹤0.01%
13,041
-6,367
-33% -$202K
BBD icon
793
Banco Bradesco
BBD
$38.3B
$355K ﹤0.01%
123,249
-16,842
-12% -$54.5K
NYT icon
794
New York Times
NYT
$12.2B
$351K ﹤0.01%
10,804
-10,656
-50% -$347K
PPLI
795
People Inc
PPLI
$3.13B
$349K ﹤0.01%
9,573
-15,976
-63% -$632K
ZD icon
796
Ziff Davis
ZD
$1.95B
$335K ﹤0.01%
4,236
-4,522
-52% -$364K
AQN icon
797
Algonquin Power & Utilities
AQN
$4.68B
$330K ﹤0.01%
50,712
-9,877
-16% -$88.1K
SPY icon
798
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
$329K ﹤0.01%
200
+47
+31% +$18.1K
RIVN icon
799
Rivian
RIVN
$24.2B
$323K ﹤0.01%
+17,509
New +$515K
RLMD icon
800
Relmada Therapeutics
RLMD
$549M
$322K ﹤0.01%
92,186
-82,419
-47% -$724K

Similar funds

Candriam SCA's Q4 2022 Portfolio in Review

As of Q4 2022, Candriam SCA held 917 positions worth $14.8B, up 4.4% from $14.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Candriam SCA's Q4 2022 filing shows 50 new, 256 increased, 457 reduced and 57 closed positions. Its largest new stake was Sarepta Therapeutics: 95,144 shares worth $12.3M. The largest sale was PepsiCo, an estimated $46.1M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q4 2022 buy was Sarepta Therapeutics: 95,144 shares worth $12.3M.
  • Candriam SCA added most to Veru in Q4 2022, an estimated $53M increase.
  • Candriam SCA's biggest Q4 2022 reduction was PepsiCo, cutting an estimated $46.1M.
  • Candriam SCA fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $24.6M.
  • Candriam SCA's ten largest holdings make up 24% of its $14.8B portfolio in Q4 2022.
  • Candriam SCA opened 50 new positions and closed 57 in Q4 2022.
  • Candriam SCA's portfolio value rose 4.4% quarter-over-quarter to $14.8B.

Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.